Sight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC increased its stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT) by 180.1% during the 4th quarter, Holdings Channel reports. The fund owned 12,076 shares of the company’s stock after purchasing an additional 7,764 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Sight Sciences were worth $62,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. US Bancorp DE purchased a new position in Sight Sciences during the fourth quarter worth approximately $27,000. Cubist Systematic Strategies LLC purchased a new position in Sight Sciences during the third quarter worth approximately $37,000. FMR LLC boosted its position in Sight Sciences by 484.6% during the second quarter. FMR LLC now owns 4,864 shares of the company’s stock worth $44,000 after purchasing an additional 4,032 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Sight Sciences by 51.0% in the third quarter. American Century Companies Inc. now owns 15,908 shares of the company’s stock valued at $54,000 after acquiring an additional 5,370 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new position in shares of Sight Sciences in the fourth quarter valued at approximately $54,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sight Sciences

In related news, COO Sam Boong Park sold 5,443 shares of Sight Sciences stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $5.16, for a total value of $28,085.88. Following the completion of the transaction, the chief operating officer now directly owns 100,735 shares in the company, valued at $519,792.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Sight Sciences news, COO Sam Boong Park sold 5,443 shares of Sight Sciences stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $5.16, for a total transaction of $28,085.88. Following the completion of the sale, the chief operating officer now directly owns 100,735 shares of the company’s stock, valued at approximately $519,792.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Badawi sold 12,571 shares of Sight Sciences stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $63,860.68. Following the sale, the chief executive officer now directly owns 5,750,729 shares of the company’s stock, valued at $29,213,703.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 63,441 shares of company stock worth $324,625. Company insiders own 27.10% of the company’s stock.

Sight Sciences Trading Down 5.4 %

Shares of NASDAQ SGHT traded down $0.30 during trading on Tuesday, reaching $5.23. The stock had a trading volume of 131,683 shares, compared to its average volume of 228,507. The company has a market cap of $259.15 million, a P/E ratio of -4.59 and a beta of 2.83. The business’s 50-day moving average price is $4.80 and its 200-day moving average price is $4.04. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $11.20. The company has a debt-to-equity ratio of 0.26, a quick ratio of 12.65 and a current ratio of 13.29.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.13. The firm had revenue of $18.75 million during the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. During the same period last year, the business posted ($0.35) earnings per share. On average, equities research analysts predict that Sight Sciences, Inc. will post -1.04 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.60.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.